BioJiva Reports Results of Pilot Phase II Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
BioJiva reported data from its completed multicenter, randomized, double-blind, placebo-controlled pilot Phase II clinical trial evaluating RT001, the company’s lead development candidate, in patients with ALS.
[Bellerophon Therapeutics, Inc.] Bellerophon Therapeutics, Inc. announced that the FDA has accepted the company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase III trial of INOpulse® for the treatment of fibrotic interstitial lung disease.
[Nature Communications] Researchers determined transcriptional changes of idiopathic pulmonary fibrosis-airway basal cells and their potential profibrotic properties using a 3D culture system and novel mouse xenograft models.
[JCI Insight] Investigators found that growth factor–β1-mediated upregulation of UHRF1 repressed Beclin1 via promoter methylation induction which resulted in fibroblast activation and lung fibrosis both in vitro and in vivo.